AMI Asset Management Corp Invests $1.44 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

AMI Asset Management Corp acquired a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 39,791 shares of the company’s stock, valued at approximately $1,438,000. AMI Asset Management Corp owned about 0.05% of SpringWorks Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SWTX. Park Avenue Securities LLC bought a new position in shares of SpringWorks Therapeutics in the 4th quarter worth $203,000. Principal Financial Group Inc. grew its position in SpringWorks Therapeutics by 102.5% in the third quarter. Principal Financial Group Inc. now owns 918,445 shares of the company’s stock worth $29,427,000 after acquiring an additional 464,903 shares in the last quarter. Exome Asset Management LLC bought a new position in SpringWorks Therapeutics in the third quarter valued at $3,226,000. Geode Capital Management LLC raised its position in SpringWorks Therapeutics by 7.0% during the third quarter. Geode Capital Management LLC now owns 1,670,247 shares of the company’s stock valued at $53,526,000 after purchasing an additional 109,189 shares in the last quarter. Finally, Barclays PLC raised its position in SpringWorks Therapeutics by 60.4% during the third quarter. Barclays PLC now owns 155,676 shares of the company’s stock valued at $4,987,000 after purchasing an additional 58,645 shares in the last quarter.

SpringWorks Therapeutics Stock Performance

Shares of SWTX stock opened at $34.63 on Tuesday. The company has a market capitalization of $2.58 billion, a P/E ratio of -8.93 and a beta of 0.82. SpringWorks Therapeutics, Inc. has a fifty-two week low of $28.21 and a fifty-two week high of $53.92. The stock has a 50 day moving average price of $38.06 and a two-hundred day moving average price of $36.32.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.03. The company had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. The firm’s revenue for the quarter was up 4810.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.27) earnings per share. As a group, equities analysts predict that SpringWorks Therapeutics, Inc. will post -3.11 earnings per share for the current year.

Insider Activity

In related news, COO Badreddin Edris sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $41.97, for a total value of $839,400.00. Following the sale, the chief operating officer now directly owns 209,600 shares of the company’s stock, valued at $8,796,912. This trade represents a 8.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.61% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on SWTX shares. Guggenheim reduced their price objective on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. HC Wainwright reduced their price target on shares of SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating on the stock in a research report on Tuesday, November 12th. Evercore ISI initiated coverage on shares of SpringWorks Therapeutics in a report on Wednesday, November 20th. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $77.00 price objective on shares of SpringWorks Therapeutics in a research note on Monday, January 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and a consensus target price of $70.00.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.